Researchers Identify Potential Therapeutic Target for Advanced Prostate Cancer

Researchers Identify Potential Therapeutic Target for Advanced Prostate Cancer
Researchers in Spain studying the 3D structure of the androgen receptor have identified a key protein for its activation called TFIIF, making it a possible therapeutic target for advanced prostate cancer. The study, “Regulation of Androgen Receptor Activity by Transient Interactions of Its Transactivation Domain with General Transcription Regulators,” was published in the journal Structure. The development and progression of prostate cancer depends on the activation of the androgen receptor (AR) protein. Depriving tumors of androgens such as testosterone or blocking the AR function are common therapies for prostate cancer. Anti-androgen drugs bind to a specific region of the AR protein and block its activity. But eventually tumors become resistant to such approaches. "Over time, the protein accumulates alterations and mutates, and there comes a point where it is futile to target this region with drugs because, in fact, it is no longer there," Xavier Salvatella, the study’s senior author and ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona), said in a press release. Patients build up a resistance to these therapies after two or three years, as they develop castration-resistant prostate cancer (CRPC). Whether by increasing AR levels, or through mutations that turn AR resistance to anti-androgen therapy, AR is st
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *